BIO CEO & Investor Conference 2014
Myth vs. reality: Rare disease drug work tougher than it looks
By Jennifer Boggs
Wednesday, February 12, 2014
NEW YORK – With so many big pharmas jumping on the rare disease bandwagon in the past few years, it might sound as though developing drugs for rare and orphan diseases was the pathway of choice.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.